Form 4: Dyne Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations and Under 10b5-1 Trading Plan
SEC Form 4 Filing
Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units and pursuant to a pre-arranged Rule 10b5-1 trading plan.
Summary
- On June 11, 2024, Wildon Farwell, the Chief Medical Officer of Dyne Therapeutics, sold 1,628 shares of common stock at a weighted average price of $31.27 to cover tax obligations related to vesting restricted stock units.
- An additional 1,008 shares were sold at $31.27 under a pre-arranged Rule 10b5-1 trading plan adopted on July 14, 2023.
- Following these transactions, Farwell directly owns 145,543 shares of Dyne Therapeutics, which includes 115,565 unvested RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales for tax obligations and under a pre-existing trading plan, which is a routine activity.
Industry Context
Sales by company insiders are a common occurrence, especially to cover tax obligations related to equity compensation or as part of pre-planned trading strategies. The use of Rule 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information.
Stakeholder Impact
- The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely minimal given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| December 10, 2021 | Date of restricted stock units granted to the Reporting Person. |
| December 9, 2022 | Date of restricted stock units granted to the Reporting Person. |
| July 14, 2023 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| June 11, 2024 | Date of the reported stock sales. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.